Pilot study on the effects of ketamine on mood and eating disorder cognitions in enduring anorexia nervosa

Randomised, double-blind, balanced crossover Phase II study (n=24) with three weekly single oral doses: ketamine 0.375 mg/kg, ketamine 0.75 mg/kg, and midazolam 0.01 mg/kg; responders (≥50% improvement on mood/anxiety ratings) may enter a 3-month open-label maintenance phase of oral ketamine 1–2× weekly.

Outcomes include mood and eating-disorder cognitions (MADRS and related instruments), 10-minute resting EEG pre/post treatment, and safety assessments performed predose, 2 hours and 24 hours after each dose.